Wells Fargo downgraded Biogen to Equal Weight from Overweight with a $240 price target, citing Skyclarys US appearing to be slowing already, EU Skyclarys likely being a 2025 story, and Leqembi uptake still being slow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- Biogen (NASDAQ:BIIB) Plunges as Earnings Disappoint
- Options Volatility and Implied Earnings Moves Today, February 13, 2024
- Biogen receives EC approval for Skyclarys
- Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
- Notable companies reporting before tomorrow’s open
